Elevated expression of DDR1 is associated with reduced survival in colorectal cancer, mediates chemoresistance in hepatocellular carcinoma, and correlates with poor prognosis in melanoma, increased invasiveness in gastric cancer, and metastasis in lung cancer [41,107,108,109,110]. Here, DDR1 is linked to gastric cancer.